Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate
Clinical Chemistry · 21 CFR 862.1357
An integrated continuous glucose monitoring system (iCGM) with sensor containing dexamethasone acetate is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time. iCGM systems are designed to reliably and securely transmit glucose measurement data to digitally connected devices, including automated insulin dosing systems, and are intended to be used alone or in conjunction with these digitally connected medical devices for the purpose of managing a disease or condition related to glycemic control. The dexamethasone acetate coating is intended to reduce inflammation at the sensor insertion site.
Recent MDR events
3,214 adverse event reports on file
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02705
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02706
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02395
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02627
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02513
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02632
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02636
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02640
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02643
- Eversense SensorJul 31, 2026MalfunctionSenseonics Inc.3009862700-2026-02625
Event type breakdown
Recalls
0 recall events for this product code
No recalls on file for this product code.
Registered firms
4 firms currently registered for this product code
510(k) clearances
2 clearances for this product code